All content for VJDementia Podcast is the property of vjdementia and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
On January 6, 2023, the US FDA approved lecanemab for the treatment of Alzheimer’s disease (AD), making history as the first ever treatment to significantly slow cognitive decline. Despite the excitement surrounding this breakthrough approval, concerns remain regarding the extent of lecanemab's clinical benefit and the risks involved with its use. In this episode, experts delve review the evidence, reflecting on the performance of lecanemab and future directions for anti-amyloid therapies.
